Angiopoietins as Potential Targets in Management of Retinal Disease.

The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.
Competing Interests: AK: Consultant: Adverum, Aerpio, Allergan, Chengdu Kanghong, DORC, Genentech, Inc., Kato, Kodiak, Novartis, Gemini, Graybug, Gyroscope, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio, Roche Research support: Adverum, Alkahest, Allegro, Allergan, Chengdu Kanghong, Gemini, Genentech, Inc., Gyroscope, Iveric Bio, NGM, Neurotech, Kodiak, Novartis, Opthea, Oxurion, Regenxbio, Recens Medical, Roche Lecture fees: Allergan, Genentech, Novartis CD: Consultant: Genentech, Roche, Regeneron, Novartis, IvericBio Research support: Genentech, Roche, Regeneron, Novartis, IvericBio, Kodiak, Adverum, Gyroscope Lecture fees: Novartis, DORC CYW: Consultant: Allergan/AbbVie, Alcon, Alimera Sciences, Novartis, Regeneron, REGENXBIO, Genentech, DORC DE: Consultant: Genentech, Regeneron, Allergan, Novartis, Notal Vision, EyePoint, Gyroscope, Kodiak, RecensMedical, DORC, IvericBio, Apellis, KKR, Regenxbio, Bausch & Lomb Research support: AsclepiX, Genentech, Bayer, Novartis, Alimera, Opthea, Ocular Therapeutix, EyePoint, Mylan, Chengdu, Gemini, Gyroscope, Kodiak, NGM, RecensMedical, Alkahest, Ionis, IvericBio, Regenxbio Lecture fees: Genentech, Bayer, Allergan, Novartis, EyePoint, DORC, Apellis Equity/Stockholder: Clearside, US Retina, Hemera Biopharmaceuticals, Boston Image Reading Center, Network Eye Founder: Network Eye RPS: Consultant: Regeneron, Genentech, Alcon, Novartis, Asclepix, Gyroscope, Bausch and Lomb. Research support: Apellis, NGM Biopharma The authors report no other conflicts of interest in this work.
(© 2021 Khanani et al.)